Therefore, it is plausible that the decrease in the NK cell population after anti-CD38 antibody exposure may have hindered the induction of effective ADCC by elotuzumab, leading to the lack of efficacy against myeloma. The gene discussed is CD38; the disease is plasma cell myeloma.